China drug regulator accepts Novo Nordisk’s application for oral Wegovy

SHANGHAI, Aug 27 (Reuters) – China’s ​drug ‌regulator has accepted ​Novo ​Nordisk’s (NOVOb.CO), marketing ⁠application ​for the ​oral version of ​its ​weight-loss drug Wegovy, ‌the ⁠Danish drugmaker said ​in ​a ⁠statement on ​Thursday.

Reporting ​by ⁠Andrew Silver ⁠in ​Shanghai; ​Editing by ​Clarence Fernandez .